This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chou, T.-C. Articles by Danishefsky, S. J. Search for Related Content PubMed PubMed Citation Articles by Chou, T.-C. Articles by Danishefsky, S. J.

Therapeutic Cure against Human Tumor Xenografts in Nude Mice by a Microtubule Stabilization Agent, Fludelone, via Parenteral or Oral Route

¹ Preclinical Pharmacology and ² Analytical Chemistry Core Laboratories, and ³ Bio-Organic Chemistry Laboratory, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center; and ⁴ Department of Chemistry, Columbia University, New York, New York

Requests for reprints: Ting-Chao Chou, Preclinical Pharmacology Core Laboratory, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Phone: 212-639-7480; Fax: 212-794-4342; E-mail: chout{at}mskcc.org.

Epothilones, 16-membered macrolides isolated from a myxobacterium in soil, exert their antitumor effect, like Taxol, by induction of microtubule polymerization and microtubule stabilization. They are effective against tumor cells that are resistant to Taxol or vinblastine. We recently designed, via molecular editing and total synthesis, a new class of epothilones represented by 26-trifluoro-(E)-9,10-dehydro-12,13-desoxy-epothilone B (Fludelone), which has emerged as a lead candidate for clinical development. Treatment of nude mice bearing MX-1 human mammary carcinoma xenografts (as large as 3.4% body weight) with Fludelone (6-hour i.v. infusion, 25 mg/kg, q3d x 5, q3d x 4) led to complete disappearance and de facto "cure" (i.e., remission without a relapse for over 15% of the average life span of 2 years). The toxicities induced by bolus i.v. injection could be avoided through prolonged i.v. infusion, which allowed for a 10-fold increase in maximal tolerated dose. Complete remission of MX-1 xenografts was achieved with only one third of this maximal tolerated dose. Parallel studies with Taxol and Fludelone [20 mg/kg, 6-hour i.v. infusion (q2d x 4) x3] against HCT-116 human colon carcinoma xenografts revealed that both drugs achieved tumor remission; however, all Taxol-treated mice relapsed in 1.3 months, whereas the Fludelone-treated mice were cured without any relapse for over 7 months. Furthermore, tumor remission was achieved by Fludelone against SK-OV-3 (ovary), PC-3 (prostate), and the Taxol-resistant CCRF-CEM/Taxol (leukemia) xenograft tumors. Most remarkably, p.o. administration of Fludelone (30 mg/kg, q2d x 7, q2d x 9, q2d x 5) against MX-1 xenografts achieved a nonrelapsing cure for as long as 8.4 months. The above results indicate that Fludelone is a highly promising compound for cancer chemotherapeutics.

This article has been cited by other articles:

				T.-C. Chou, X. Zhang, Z.-Y. Zhong, Y. Li, L. Feng, S. Eng, D. R. Myles, R. Johnson Jr, N. Wu, Y. I. Yin, et al. Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones PNAS, September 2, 2008; 105(35): 13157 - 13162. [Abstract] [Full Text] [PDF]

				C. F. Beyer, N. Zhang, R. Hernandez, D. Vitale, J. Lucas, T. Nguyen, C. Discafani, S. Ayral-Kaloustian, and J. J. Gibbons TTI-237: A Novel Microtubule-Active Compound with In vivo Antitumor Activity Cancer Res., April 1, 2008; 68(7): 2292 - 2300. [Abstract] [Full Text] [PDF]

				T.-C. Chou Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies Pharmacol. Rev., September 1, 2006; 58(3): 621 - 681. [Abstract] [Full Text] [PDF]